Literature DB >> 1086696

Multidisciplinary treatment for macrometastatic osteogenic sarcoma.

N Jaffe, D Traggis, J R Cassady, R M Filler, H Watts, E Frei.   

Abstract

Using a co-ordinated multidisciplinary approach with surgery, radiation therapy, and chemotherapy, 14 out of 21 patients with metastases from osteogenic sarcoma were rendered free of disease for over two to over 18 months. Most patients had pulmonary metastases, two had bony metastases, and one had metastases in the iliac nodes. As part of this multidisciplinary approach weekly high-dose methotrexate was given and caused tumour regression in seven out of 15 patients. After all clinical evidence of disease had been removed high-dose methotrexate was administered every two to three weeks as maintenance treatment. To assess the efficacy of treatment the results were compared with those in a historical control group of 82 consecutive patients who developed pulmonary or other metastases. The results in the study group were significantly better. This experience may be similar to that in Wilms's tumour, where actinomycin D has increased the cure rate when administered as adjuvant therapy after treatment of localised or overt metastatic disease.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1086696      PMCID: PMC1689090          DOI: 10.1136/bmj.2.6043.1039

Source DB:  PubMed          Journal:  Br Med J        ISSN: 0007-1447


  8 in total

1.  Maximum utilization of the life table method in analyzing survival.

Authors:  S J CUTLER; F EDERER
Journal:  J Chronic Dis       Date:  1958-12

2.  Favorable response of metastatic osteogenic sarcoma to pulse high-dose methotrexate with citrovorum rescue and radiation therapy.

Authors:  N Jaffe; D Paed; S Farber; D Traggis; C Geiser; B S Kim; L Das; G Frauenberger; I Djerassi; J R Cassady
Journal:  Cancer       Date:  1973-06       Impact factor: 6.860

3.  High-dose methotrexate with citrovorum factor rescue and adriamycin in childhood osteogenic sarcoma.

Authors:  G Rosen; S Suwansirikul; C Kwon; C Tan; S J Wu; E J Beattie; M L Murphy
Journal:  Cancer       Date:  1974-04       Impact factor: 6.860

4.  Considerations in the radiation therapy of Wilms' tumor.

Authors:  J R Cassady; M Tefft; R M Filler; N Jaffe; D Paed; S Hellman
Journal:  Cancer       Date:  1973-09       Impact factor: 6.860

5.  Chemotherapy in the treatment of leukemia and Wilms' tumor.

Authors:  S Farber
Journal:  JAMA       Date:  1966-11-21       Impact factor: 56.272

6.  Doxorubicin in disseminated osteosarcoma.

Authors:  E P Cores; J F Holland; J J Wang; L F Sinks
Journal:  JAMA       Date:  1972-09-04       Impact factor: 56.272

7.  Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma.

Authors:  G Rosen; M L Murphy; A G Huvos; M Gutierrez; R C Marcove
Journal:  Cancer       Date:  1976-01       Impact factor: 6.860

8.  Combination chemotherapy and radiation therapy in the treatment of metastatic osteogenic sarcoma.

Authors:  G Rosen; M Tefft; A Martinez; W Cham; M L Murphy
Journal:  Cancer       Date:  1975-03       Impact factor: 6.860

  8 in total
  3 in total

1.  Pharmacokinetic and clinical studies of 24-h infusions of high-dose methotrexate.

Authors:  H J Cohen; N Jaffe
Journal:  Cancer Chemother Pharmacol       Date:  1978       Impact factor: 3.333

2.  [Multidrug chemotherapy of osteogenic sarcoma (author's transl)].

Authors:  G Prindull
Journal:  Blut       Date:  1979-10

3.  Clinical epidemiology and treatment outcomes of spindle cell non-osteogenic bone sarcomas - A nationwide population-based study.

Authors:  Kjetil Berner; Tom Børge Johannesen; Kirsten Sundby Hall; Øyvind S Bruland
Journal:  J Bone Oncol       Date:  2018-11-20       Impact factor: 4.072

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.